DECLARE‐TIMI 58: Participants’ baseline characteristics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

DECLARE‐TIMI 58: Participants’ baseline characteristics

Published:2018-05 Issue:5 Volume:20 Page:1102-1110
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Raz Itamar¹^ORCID,Mosenzon Ofri¹,Bonaca Marc P.²,Cahn Avivit¹^ORCID,Kato Eri T.³,Silverman Michael G.²,Bhatt Deepak L.²^ORCID,Leiter Lawrence A.⁴^ORCID,McGuire Darren K.⁵,Wilding John P. H.⁶^ORCID,Gause‐Nilsson Ingrid A. M.⁷,Langkilde Anna M.⁷,Johansson Peter A.⁷,Sabatine Marc S.²,Wiviott Stephen D.²

Affiliation:

1. Diabetes Unit, Department of Internal MedicineHadassah Hebrew University Hospital Jerusalem Israel

2. TIMI Study Group, Division of Cardiovascular MedicineBrigham and Women's Hospital, and Harvard Medical School Boston Massachusetts

3. Kyoto University Hospital Kyoto Japan

4. Li Ka Shing Knowledge InstituteSt. Michael's Hospital, University of Toronto Toronto Ontario Canada

5. University of Texas Southwestern Medical Center Dallas Texas

6. Obesity and Endocrinology Research GroupUniversity of Liverpool Liverpool UK

7. AstraZeneca Gothenburg Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13217

Reference39 articles.

1. Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

2. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

3. Biology of Human Sodium Glucose Transporters

4. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

5. Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings;Journal of Endocrinology and Metabolism;2024-06

2. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

3. Modern approaches to the treatment of diabetes mellitus: A review. Moscow City Congress of Endocrinologists “Endocrinology of the capital – 2024”. Review of the congress on March 29–31, 2024;Consilium Medicum;2024-05-20

4. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial;Clinical Kidney Journal;2024-02-01

5. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3